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INTRODUCTION
A common goal of protein engineering is to enhance
recombinant protein binding to .a cell or to another
macromolecule. A typical strategy involves modifying
individual protein binding sites to increase their affinity
for target molecules, but this may not improve specificity
of binding. Significantly enhanced binding selectivity
may arise, in principle, from multisite binding interac-
tions of low individual affinity. Binding species that
generally meet these criteria may utilize engineered
antibody binding sites, such as modified single-chain Fv
(sFv) proteins (1-4), directed against any antigen of
interest. The present research sought to remedy a
practical biomedical problem: disease-related immune
complexes (ICs) can be removed from human serum by
immobilized staphylococcal protein A, but only with
accompanying depletion of free IgG, thereby compromis-
ing patients' humoral immunity. As the basis for an
affinity separation device that would exclusively bind ICs
in normal serum, we devised truncated analogues of the
B domain of staphylococcal protein A (5) that bound
monomeric IgG with greatly reduced affinity. Other
workers studied an immobilized peptide from C1q which
exhibited selectivity for immune complexes (6). How-
ever, our experiments were designed to test this multi-
site binding hypothesis by comparing the binding of ICs
and IgG in serum by immobilized FB species of high and
low affinity.
MATERIALS AND METHODS
Several truncated fragment B analogues were prepared, which are
designated by the number of residues retained from the 58 residue
sequence of the parent B domain in staphylococcal protein A (Table
1). The FB 58 and FB 29 genes were prepared from synthetic
oligonucleotides (1, 5), encoding the protein sequences given in Table
1. The FB 58 protein and its analogues were produced by recombinant
DNA methodology with direct or fusion protein expression in Escheri-
chia coli (1-5), and FB 51 was prepared by tryptic cleavage of FB 58.
Cysteine was added to these sequences for purposes of immobilization;
the FB genes were modified so that the FB 58 sequence was preceded
by Met-A1a-Cys, while the FB 29 sequence was preceded by Met-Pro-
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A1a-Cys. The MAC-FB 58 was expressed directly in E. coli, whereas
tandem repeats of 3 or 4 MPAC-FB 29 genes were expressed as fusion
proteins that fonned inclusion bodies. The MPAC-FB 29 fusion
protein was treated with cyanogen bromide (0.25 gig cell paste) in 0.1
N HCI and was purified by HPLC (5), resulting in mixtures of species
with and without COOH-terminal homoserine lactone; the PAC-FB
29 binding properties appeared insensitive to this slight heterogeneity.
Cysteine-containing proteins were immobilized on diaminodipro-
plyamine-Sepharose CL-4B that was first modified with m-maleimido-
benzoyl sulfosuccinimide (sulfo-MBS; Pierce Chemical Co., Rockford,
IL) (5).
The relative affinities of FB analogues (Table 1) were determined by
competition radioimmunoassays in which a dilution series of a given
FB analogue was incubated with HulgG-coated polyvinyl chloride
microtiter plates; after washing, a constant quantity of 'lSl-labelled FB
58 was incubated with each well to determine the percent saturation by
analogue compared to control wells devoid of analogue; the relative
percent inhibition by a given analogue was plotted as a function of its
concentration. Using an experimental estimate for recombinant FB 58
binding to HuigG of I<.-'PP = 2.5 X 107 M-' (1), the unknown binding
constant was calculated as the product of this 1<.""" value times the
quotient of the 50% inhibition concentration of FB 58 divided by that
of the truncated FB analogue.
Chemically aggregated IgG (denoted CAG in Table 2) was prepared
by carbodiimide cross-linking, and the tetrameric M, 600,000 protein
fraction was isolated by size exclusion chromatography; experiments
also involved heat aggregated IgG as model ICs. Concentrations of
CAG as a model immune complex were measured by a circulating
immune complex assay kit from Cytotech (San Diego, CA), wherein
concentrations of an unknown IC are related to a reference curve
based on a heat aggregated IgG standard, and IC levels are given in J.l.g
equivalents of the standard per ml (J.l.g Eq/ml). Free human IgG
(HulgG) concentrations were measured by radioimmunoassay (5) in
nonnal human serum (NHS) or in CAG-NHS mixtures before and
after resin treatment. In the IC binding experiments, 100 J.l.1 of
CAG/NHS or NHS were added to 100 J.l.1 of resin (varied as noted in
Table 2) pelleted by centrifugation in an Eppendorf tube (Table 2);
following incubation, the suspension was respun in an Eppendorf
centrifuge, the supernatant solution was saved and pooled with an
additional 100 J.l.1 wash of each resin pellet, and subsequently assayed.
RESULTS AND DISCUSSION
The rationale for generating the low affinity FB ana-
logues was primarily based on the crystal structure of FB
58 complexed with human Fc (7). Deisenhofer found
that FB residues 5-47 were identifiable as a core bound
to the Fc fragment, but residues 1-4 and 48-58 were not
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TABLE 1 sequences of truncated FB analogues and their t<..- values for binding to human IgG
Helix designation: II III
7 8 36 48 58
FB 58 ADNKFNK EQQNAFYEILHLPNLNEEQRNGFIQSLKD DPSQSANLLAEAKKLNDAQAPK I<."pp = 2.5 X 10' M-'
FB29
36
EQQNAFYEILHLPNLNEEQRNGFIQSLKD 2 X 102 < I<."pp < 1 x 10' M- '
36
FB 36 ADNKFNK EQQNAFYEILHLPNLNEEQRNGFIQSLKD v = 1 X IO'M-'J.'"a,app
FB40
47
EQQNAFYEILHLPNLNEEQRNGFIQSLKD DPSQSANLLAE 3 X 10' < I<."pp < 1 X 104 M- '
47
FB 47 ADNKFNK EQQNAFYEILHLPNLNEEQRNGFIQSLKD DPSQSANLLAE I<."pp = 1 x 10' M- '
FB51
58
EQQNAFYEILHLPNLNEEQRNGFIQSLKD DPSQSANLLAEAKKLNDAQAPK I<."pp = 2.5 X 106 M- '
Polypeptide sequence is given in single letter code; underlined helices I and II were defined in crystals (7) and III in solution (11).
TABLE 2 Levels of model Immune complexes and human IgG after resin adsorption
Immune complex or human IgG concentration after resin adsorption
Resin Measured 1 mgFB/ml 2mgFB/ml 3mgFB/ml 4mgFB/ml
conjugate Ig source species No resin Control resin resin resin resin resin
FB29 CAG/NHS IC' 21.0 18.3 12.7 10.3 8.0 7.0
HuIgG* 4.03 3.70 3.73 3.04 3.72 3.55
FB58 CAG/NHS IC 21.0 18.3 10.2 9.1 7.0 8.0
HuIgG 4.03 3.70 2.11 1.49 0.99 0.90
FB29 NHS IC 2.2 1.6 n.d.1 n.d. n.d. 0.8
HuIgG 3.82 3.10 2.78 3.46 3.26 3.39
FB58 NHS IC 2.2 1.6 n.d. n.d. n.d. 0.2
HuIgG 3.82 3.10 1.97 1.07 1.04 0.92
'Concentration of immune complexes is expressed in !kg Eq/ ml (note Materials and Methods). *Concentration of human IgG is given in mg/ml.
In.d. Not determined.
accounted for in the FB-Fc electron density maps. This
core comprises two antiparallel a-helices that are de-
noted I and II in Table 1. Thus, our strategy was to
preserve most of this core so that it could maintain its
specificity of binding to the Fc, and we progressively
deleted parts of the flanking polypeptide sequence as a
means for reducing its Fc-binding affinity. This approach
generated analogue affinities ranging from -IOZ M- 1 to
FIGURE 1 Structural views of the fragment B and its contacts with the Fc region, based on Deisenhofer's crystallographic analysis of FB 58
complexed with human Fc fragments (7). FB 58 (represented by space-filling models in all panels except B) binds to Fc at the junction of its c,.2
and c,.3 domains (shown as blue ribbons tracing the peptide backbone). The approximate Fc interactions with FB 58 are displayed as a yellow dot
surface showing contours of Fc atoms within 4 Aof the FB 58. The FB helix axes are parallel to the page in the left series of pictures, while the FB
helix axes are orthogonal to the page in the right series. X-ray diffraction studies localized only 43 residues of the FB 58 polypeptide in electron
density maps (7), and therefore, only residues 5-47 are displayed inA-D; E and F display residues 8-36, representing the FB 29 portion of FB 58 in
the parent structure. (A) FB 58 oriented with its Fc interaction surface visible through the Fc ribbon profile. Color scheme for A, C, and D: atoms in
residues 5-7 and 37-47 are light gray, except for the red sidechain of Phe-5, which contacts the Fc; atoms in residues 8-36 corresponding to FB 29
are purple, except for lavender side-chains, which contact the Fc region. (B) Side view of the FB-Fc complex with both displayed as ribbon profiles;
the chain termini of FB 29 (purple ribbon) are facing toward the reader; the crystallographically defined residues in FB 58 that flank FB 29 are
shown as white ribbons (residues 5-7 on the NH2-terminal side, and partially helical residues 37-47 on the COOH-terminal side). (C) Solvent
accessible side ofFB 58 complexed to Fc (a two-fold rotation of viewA; color scheme is the same as for A). (D) Right side of structure in C, viewed
along the axes of helices I and II; color scheme is the same as for A. (E) FB 29 portion of the FB 58 crystal structure shown in C; peptide backbone
is light blue, side-chains contacting Fc are lavender, and other side-chains are purple. (F) Right side of structure in E, viewed along the axes of
helices I and II; color scheme is identical to that for E.
Molecular modeling was conducted on a Silicon Graphics 4D-70 GTX Superworkstation (Silicon Graphics, Mountain View, CA) using
coordinates from the IFC2 coordinates (version: January 1990) for the FB-Fc structure (7) obtained from the Brookhaven Protein Data Bank (9)
and modeled with the Insight II Program (Biosym Technologies, Inc., San Diego, CA).
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106 M- I (Table 1), which at the lower extreme corre-
sponds to a dissociation constant of 10-2 M that virtually
precludes single-site binding to IgG at its normal serum
concentration of - 5 x 10-5 M.
FB analogues immobilized at 1-4 mg/ml of resin
provided sufficient binding site density to demonstrate
validity of the multisite binding hypothesis. As the
density of immobilized FB 29 protein was increased, the
ICs were preferentially removed from CAG/NHS and
NHS in a dose dependent manner while leaving IgG at
control levels (Table 2). In relation to control resin
devoid of FB, the FB 29 resins bound 41-60% of the
CAG with negligible binding of monomeric IgG, whereas
the FB 58 resin bound the CAG similarly but its resin
conjugates reduced the HuIgG level by 43-76% (Table
2).
This research has demonstrated that immobilized FB
29 having a low intrinsic affinity for the Fe region of IgG
exhibited a marked preference for binding immune
complexes over free IgG, whereas immobilized FB 58
exhibited no such preferential binding. The interactions
involved in this experiment can be readily interpreted in
terms of the unitary free energy change (8) resulting
from a single binding interaction (aGu) versus multisite
interaction at n sites (naGu)' Corresponding Ko values,
calculated using molal concentrations, would then be Ko
for IgG versus Kri for the (IgG)4 model ICs noted above;
for FB 29 binding to monomeric IgG with a Ko of 102 m-\
it would bind four sites on the IC with a maximum Ko of
108 m- I •
The specificity shown by FB 29 in binding IgG
multimers (Table 2) is consistent with its retention of
essential Fe-complementarity exhibited by the FB 58
(Fig. 1). Given the practical advantages of working with
a functional B domain analogue of the lowest molecular
weight and affinity, we utilized FB 29 with only half of
the parent B domain polypeptide (residues 8-36) and
K..app between 2 x 102 M- I and 1 x 103 M- 1• However,
the dramatic reduction of Fe-binding affinity achieved by
deleting COOH-terminal residues (Table 1) raises signif-
icant question about the physical basis for Fe binding by
intact B domain. Most of this affinity change was
effected by elimination of the COOH-terminal 11 resi-
dues of the parent FB 58, leading to FB 47 (residues
1-47) with K..app of 1 x 103 M- I • Although this COOH-
terminal segment was not crystallographically defined in
the FB-Fc complex (7), it was shown by solution NMR to
contribute to helix III formation in the Fc-free state
(helix III consists of residues 41-54 in our FB 58
sequence) (10, 11). Deletion of 7 residues at the amino-
terminus in FB 51 only lowered K..app to 2.5 X 106 M-\
which emphasizes the importance of this COOH-
terminal segment to FB 58 association with the Fc
region. Simple electrostatic effects do not provide a
rationale for the observed order of FB analogue Fc-
affinities (Table 1), as the net charge calculated at
neutral pH showed the Fe to be positive and various
truncated FB forms to be negative, with weak binding
FB 47 and FB 29 analogues both more negative than FB
58. This high affinity binding phenomenon appears to
involve functional linkage (12) between the COOH-
terminal helix-coil transition and the FB 58-Fc interac-
tion (10, 11). Truncated forms of the B domain appear
to hold promise for the removal of circulating immune
complexes by extracorporeal perfusion (13) and for
biophysical analysis of FB-Fc association.
This approach may be extended to multisite binding
with other recombinant molecules, such as single-chain
Fv analogues and fusion proteins (2). These may be
individually immobilized on a suitable matrix for affinity
fractionation or fused to each other for solution target-
ing (2, 4). Use of a single form of low-affinity sFv would
be analogous to this FB example. If two or more distinct
sFv species were used together, specificity could be
enhanced further for multi-determinant antigens or
multi-antigen cell surfaces.
Molecular modeling and single-chain Fv research were supported in
part by National Institutes of Health grants CA39870 and CA51880.
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